ADMA
What one share of Adma Biologics holds
Biological Products, (No Diagnostic Substances)
We are a U.S. based end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases.
Adma Biologics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $2.14 |
|---|---|
| Profit | $0.70 |
| Capex (buildings and equipment) | $0.08 |
| Free cash flow | $0.49 |
| Cash and investments | $0.60 |
| Debt | $0.87 |
| Book value | $1.81 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $0.88 | −$1.61 | $0.01 | −$1.51 | — | −$0.35 |
| 2017 | $0.99 | −$1.91 | $0.12 | −$1.74 | — | $1.10 |
| 2018 | $0.38 | −$1.45 | $0.05 | −$1.43 | — | $0.43 |
| 2019 | $0.54 | −$0.89 | $0.07 | −$1.47 | — | $0.44 |
| 2020 | $0.49 | −$0.88 | $0.15 | −$1.33 | — | $0.84 |
| 2021 | $0.58 | −$0.51 | $0.10 | −$0.90 | — | $0.72 |
| 2022 | $0.78 | −$0.33 | $0.07 | −$0.37 | — | $0.69 |
| 2023 | $1.15 | −$0.13 | $0.02 | $0.02 | — | $0.60 |
| 2024 | $1.75 | $0.81 | $0.03 | $0.45 | — | $1.48 |
| 2025 | $2.08 | $0.60 | $0.09 | $0.11 | — | $2.01 |